Home LiteratureArticle Details
PMID: 20048700 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Current opinion in HIV and AIDS ·Vol. 4 ·No. 5 ·2009-09-00 ·Pages 373-9

Tomaras GD, Haynes BF

Abstract

The humoral immune response to HIV-1 throughout infection is comprised of complex mixtures of antibody isotypes with numerous HIV-1 specificities. However, unlike antibody responses to most infections, protective antibody responses are delayed and do not arise until long after HIV-1 latency is established. We review recent data on HIV-1-specific antibody isotypes induced following HIV-1 transmission: to understand the effects of HIV-1 on B cell and T cell effector responses, to understand the timing of the rise and fall of different anti-HIV-1 antibodies and to understand how antibodies could contribute to protective immunity if they were either pre-existing or elicited immediately after HIV-1 transmission. Studies of the earliest events following infection by the transmitted/founder virus have recently revealed that early destruction of B cell generative microenvironments may be responsible for delay of potentially protective anti-HIV-1 antibody responses. Unlike the initial CD8 T cell response to HIV-1, the initial induced antibody response is usually ineffective in controlling virus replication during acute HIV-1 infection. The antibody isotypes and specificities elicited during HIV-1 infection can provide a window into deciphering the detrimental effects of HIV-1 on B cell and T cell responses. Additionally, further characterization of the virus inhibitory capabilities of anti-HIV-1 antibody isotypes can define the spectrum of potential protective HIV-1 antibodies that could be readily elicited by experimental vaccines and adjuvants.

MeSH Terms
HIV Antibodies/blood HIV Infections/immunology HIV-1/immunology Humans
Chemicals
HIV Antibodies
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Tomaras Georgia D
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. gdt@duke.edu
Haynes Barton F
References (74)
74 references, click to expand
  1. A method for identification of HIV gp140 binding memory B cells in human blood.
    J Immunol Methods. 2009 Apr 15;343(2):65-7 PMID: 19100741
  2. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.
    J Virol. 1997 Apr;71(4):2799-809 PMID: 9060635
  3. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus.
    Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):228-30 PMID: 3004634
  4. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.
    J Virol. 2001 Jul;75(14):6558-65 PMID: 11413323
  5. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.
    J Virol. 2008 Feb;82(4):1860-9 PMID: 18057243
  6. Role of complement in the control of HIV dynamics and pathogenesis.
    Vaccine. 2003 Jun 1;21 Suppl 2:S77-82 PMID: 12763687
  7. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    J Virol. 2007 Feb;81(3):1424-32 PMID: 17121806
  8. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
    Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7 PMID: 18490657
  9. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression.
    AIDS. 2008 Nov 12;22(17):2257-65 PMID: 18981765
  10. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors.
    Biochem J. 1989 Apr 15;259(2):347-53 PMID: 2524188
  11. The regulation of IgA class switching.
    Nat Rev Immunol. 2008 Jun;8(6):421-34 PMID: 18483500
  12. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1--infected women.
    J Infect Dis. 2002 Feb 15;185(4):439-47 PMID: 11865395
  13. Fc receptors and their interactions with immunoglobulins.
    Annu Rev Cell Dev Biol. 1996;12:181-220 PMID: 8970726
  14. Antibody response to human immunodeficiency virus in homosexual men. Relation of antibody specificity, titer, and isotype to clinical status, severity of immunodeficiency, and disease progression.
    J Clin Invest. 1987 Aug;80(2):316-24 PMID: 3497176
  15. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  16. Dimers are a girl's best friend.
    Nat Med. 1997 Nov;3(11):1199-200 PMID: 9359691
  17. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 PMID: 12644702
  18. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
    J Virol. 2009 Apr;83(8):3617-25 PMID: 19193787
  19. IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection.
    J Immunol. 1989 Jun 1;142(11):3809-14 PMID: 2497181
  20. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors.
    J Immunol. 2006 Apr 1;176(7):3931-41 PMID: 16547227
  21. Neutralizing inter-clade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts.
    AIDS. 2009 Oct 23;23(16):2219-22 PMID: 19830891
  22. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.
    J Virol. 2007 Feb;81(3):1350-9 PMID: 17079307
  23. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
    J Virol. 2008 Dec;82(24):12449-63 PMID: 18842730
  24. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
    J Virol. 2009 Jul;83(14):7337-48 PMID: 19439467
  25. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Expert Rev Vaccines. 2006 Jun;5(3):347-63 PMID: 16827619
  26. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
    J Virol. 2009 Aug;83(15):7397-410 PMID: 19458010
  27. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Virology. 2009 May 10;387(2):414-26 PMID: 19298995
  28. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.
    Curr HIV Res. 2007 Nov;5(6):542-53 PMID: 18045110
  29. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.
    Clin Exp Immunol. 1988 Sep;73(3):343-7 PMID: 3208446
  30. Antibodies, viruses and vaccines.
    Nat Rev Immunol. 2002 Sep;2(9):706-13 PMID: 12209139
  31. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection.
    PLoS Med. 2009 Jul 7;6(7):e1000107 PMID: 19582166
  32. Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG.
    J Infect Dis. 1987 Dec;156(6):1026-30 PMID: 3479499
  33. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.
    Nature. 2009 Apr 2;458(7238):636-40 PMID: 19287373
  34. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses.
    Nat Med. 1998 Aug;4(8):945-8 PMID: 9701248
  35. IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease.
    Clin Immunol Immunopathol. 1991 Feb;58(2):267-77 PMID: 1985797
  36. Analysis of a subclass-restricted HIV-1 gp41 epitope by omission peptides.
    Immunology. 1989 May;67(1):1-7 PMID: 2472353
  37. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.
    AIDS. 2003 Sep 5;17(13):1871-9 PMID: 12960819
  38. Isotypic restriction of the antibody response to human immunodeficiency virus.
    AIDS Res Hum Retroviruses. 1988 Feb;4(1):3-9 PMID: 3163253
  39. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    J Virol. 2009 Jan;83(2):757-69 PMID: 18987148
  40. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.
    AIDS. 2009 May 15;23(8):897-906 PMID: 19414990
  41. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis.
    Lancet. 1987 Jan 17;1(8525):119-22 PMID: 2879968
  42. B cells in HIV infection and disease.
    Nat Rev Immunol. 2009 Apr;9(4):235-45 PMID: 19319142
  43. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.
    J Infect Dis. 2005 Jun 15;191(12):2053-63 PMID: 15897991
  44. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.
    PLoS Pathog. 2007 Nov;3(11):e169 PMID: 17983270
  45. Immunoglobulin class- and subclass-specific HIV antibody detection in serum and CSF specimens by ELISA and Western blot.
    Infection. 1987;15(5):317-22 PMID: 3480270
  46. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
    Clin Exp Immunol. 1995 Feb;99(2):175-81 PMID: 7851008
  47. Isotypic distribution of HIV-1-specific antibodies in individuals from central Africa.
    Viral Immunol. 1992 Winter;5(4):243-8 PMID: 1472277
  48. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression.
    AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1435-46 PMID: 11679156
  49. The immune response to thetaX 174 in man. I. Primary and secondary antibody production in normal adults.
    Clin Exp Immunol. 1973 Apr;13(4):497-513 PMID: 4197826
  50. Fc receptor but not complement binding is important in antibody protection against HIV.
    Nature. 2007 Sep 6;449(7158):101-4 PMID: 17805298
  51. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
    Clin Exp Immunol. 1989 May;76(2):216-21 PMID: 2503275
  52. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome.
    J Infect Dis. 1986 May;153(5):970-3 PMID: 3009638
  53. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.
    J Virol. 2009 Apr;83(8):3719-33 PMID: 19176632
  54. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.
    Br Med J (Clin Res Ed). 1986 Dec 6;293(6560):1459-62 PMID: 3099912
  55. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  56. Critical issues in mucosal immunity for HIV-1 vaccine development.
    J Allergy Clin Immunol. 2008 Jul;122(1):3-9; quiz 10-1 PMID: 18468671
  57. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.
    BMJ. 1991 Jan 5;302(6767):23-6 PMID: 1899349
  58. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    Nat Med. 2009 Aug;15(8):866-70 PMID: 19525964
  59. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1.
    J Immunol. 2001 May 15;166(10):6257-65 PMID: 11342649
  60. Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.
    AIDS. 1987 Dec;1(4):235-40 PMID: 3126771
  61. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM.
    Immunity. 1998 Aug;9(2):277-87 PMID: 9729048
  62. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.
    J Virol. 2009 Apr;83(8):3556-67 PMID: 19193811
  63. IgG Fc receptors.
    Annu Rev Immunol. 2001;19:275-90 PMID: 11244038
  64. Markers for progression in HIV infection.
    AIDS. 1989;3 Suppl 1:S153-60 PMID: 2575397
  65. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations.
    AIDS. 2004 Nov 19;18(17):2253-9 PMID: 15577537
  66. FcgammaRIIa genotype predicts progression of HIV infection.
    J Immunol. 2007 Dec 1;179(11):7916-23 PMID: 18025239
  67. An aberrant subclass pattern of HIV-specific immunoglobulin G in sera from haemophiliacs.
    AIDS. 1988 Aug;2(4):311-3 PMID: 3140836
  68. Isotype profiles of anti-gp160 antibodies from HIV-infected patients in plasma and culture supernatants.
    Immunol Lett. 2004 Apr 30;93(1):57-62 PMID: 15134900
  69. Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity.
    AIDS. 2008 Nov 12;22(17):2401-2 PMID: 18981783
  70. Deterioration in immunologic status of human immunodeficiency virus (HIV)-infected homosexual men with lymphadenopathy: prognostic implications.
    J Clin Immunol. 1989 Mar;9(2):132-8 PMID: 2523901
  71. Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history.
    Clin Diagn Lab Immunol. 2005 Jul;12(7):845-7 PMID: 16002633
  72. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
    J Virol. 2008 Dec;82(23):11651-68 PMID: 18815292
  73. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV.
    AIDS Res Hum Retroviruses. 2009 Jan;25(1):83-92 PMID: 19108692
  74. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers.
    AIDS. 2008 Mar 30;22(6):727-35 PMID: 18356602
Article Info
Journal
Current opinion in HIV and AIDS
Abbr.
Curr Opin HIV AIDS
ISSN
1746-6318
DOI
10.1097/COH.0b013e32832f00c0
Email
gdt@duke.edu
Published
2009-09-00
Pages
373-9
Language
English
Region
United States
NLM ID
101264945
PMCID
PMC3133462
Subset
IM
Grants
NIAID NIH HHS · U19 AI067854-06 · United States
NIAID NIH HHS · U01 AI067854 · United States
NIAID NIH HHS · P01 AI061734 · United States
NIAID NIH HHS · U19AI067854 · United States
NIAID NIH HHS · R01 AI052779 · United States
NIAID NIH HHS · P01 AI052816 · United States
NIAID NIH HHS · R01AI052779 · United States
NIAID NIH HHS · U01 AI046725 · United States
NIAID NIH HHS · UM1 AI068618 · United States
NIAID NIH HHS · R01 AI052779-06 · United States
NIAID NIH HHS · P30 AI064518 · United States
NIAID NIH HHS · U01 AI068618 · United States
NIAID NIH HHS · AI068618 · United States
NIAID NIH HHS · U19 AI067854 · United States
External Links
PubMed source DOI: 10.1097/COH.0b013e32832f00c0 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2